克罗恩病治疗市场：按药物类型、按分销渠道、按地区 - 规模、份额、前景、机会分析，2022-2030

克罗恩病是一种导致消化道炎症的慢性炎症性肠病 (IBD)。这种炎症可以发生在小肠迴肠和大肠结肠之间的任何地方。克罗恩病的常见症状从轻微到严重不等，包括腹痛、食慾不振、发烧和频繁腹泻。肛管发炎的裂缝也会导致直肠出血。导致克罗恩病的因素包括遗传基因、导致炎症的自身免疫反应以及细菌和病毒等环境因素。这种疾病主要影响 15 至 35 岁的人群，并且影响男性和女性。

虽然这种疾病没有灵丹妙药，但各种治疗方法可以减轻疾病的症状和体征，带来长期的缓解。抗炎药、免疫抑製剂、抗生素和其他抑制炎症的药物被用于治疗克罗恩病，并有望改善长期预后。

市场动态

北美和欧洲的克罗恩病等炎症性肠病 (IBD) 发病率很高，预计这将推动市场增长。例如，根据 2020 年 12 月发表在《消化医学研究》上的一篇论文，预计到 2030 年，IBD 的患病率将在北美达到约 400 万人。根据同一来源，加拿大数据估计，2018 年 IBD 的患病率为每 10 万人 725 人，到 2030 年上升至每 10 万人 981 人。因此，预计 IBD 患病率的增加将在预测期内推动市场增长。

本研究的主要特点

• 本报告对全球克罗恩病治疗市场进行了深入分析，揭示了以 2021 年为基准年的预测期内（2022-2030 年）的市场规模（十亿美元）和復合年增长率 (CAGR%)
• 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
• 该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 根据公司亮点、产品组合、关键亮点、财务业绩和战略等参数，对全球克罗恩病治疗市场的主要参与者进行简介。
• 本研究涉及的主要公司包括 AbbVie Inc.、Janssen Biotech, Inc.、Bristol-Myers Squibb Company、Boehringer Ingelheim GmbH、Pfizer Inc.、Eli Lilly and Company、Novartis AG、Sanofi、Takeda Pharmaceutical Company Limited 、Mylan N.V.、安进公司和阿斯利康
• 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 全球克罗恩病治疗市场报告面向该行业的各种利益相关者，包括投资者和供应商、产品製造商、分销商、新进入者和财务分析师。
• 利益相关者可以通过在分析全球克罗恩病治疗市场时使用的各种策略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 举报内容
  • 市场定义和范围
• 执行摘要
  • 按药物类型划分的市场概况
  • 市场快照：按分销渠道
  • 市场概况：按地区划分
• 连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 驱动程序
  • 约束因素
  • 市场机会
• 影响分析
• 主要亮点
• 市场趋势
• PORTER 的五力分析
• 流行病学
• 新品发布
• 产品类型创新

第 4 章克罗恩病药物全球市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 对供需的影响
• COVID-19 对市场的影响

第 5 章克罗恩病药物全球市场：按药物类型，2017-2030 年

• 抗生素
• 氨基水杨酸盐
• 皮质类固醇
• 免疫调节剂
• 其他

第 6 章按分销渠道分列的克罗恩病药物全球市场：2017-2030

• 医院药房
• 零售药房
• 电子商务

第 7 章。按地区分列的克罗恩病药物全球市场，2017-2030 年

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海合会
• 以色列
• 其他中东
• 非洲
• 北非
• 中非
• 南非

第 8 章竞争格局

• AbbVie Inc.
• Janssen Biotech, Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• Sanofi
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Amgen Inc.
• AstraZeneca

第九章章节

• 调查方法
• 关于出版商

Crohn's disease is a form of chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal tract. This inflammation can take place anywhere between the ileum of the small intestine to the colon of the large intestine. Common symptoms of Crohn's disease from mild to severe intensity include abdominal pain, reduced appetite, fever, and frequent diarrhea. Rectal bleeding is encountered in few cases due to fissures from inflammation at anal canal. Factors responsible for causing Crohn's disease include hereditary genes, autoimmune reaction that causes inflammatory condition, and environmental factors such as bacteria and virus. The disease majorly affects people falling between age group of 15-35 years and occurs in both males and females.

There exists no specific cure for the disease, however various therapies can be employed on patients that can help to reduce signs and symptoms of the disease as well as can bring long-term remission. Improvement in long-term prognosis can be achieved through several medications prescribed for the treatment of Crohn's disease that include anti-inflammatory drugs, immune system suppressers, antibiotics and other medication that helps to control inflammation.

Market Dynamics

The North America and Europe regions have high incidence of inflammatory bowel disease (IBD) such as Crohn's disease, which is expected to drive growth of market. For instance, according to an article published in the journal Digestive Medicine Research in December 2020, in North America, the prevalence of IBD is projected to affect approximately 4 million persons by 2030. According to the same source, data from Canada reported a prevalence of IBD at 725 per 100,000 in 2018, which is estimated to rise to 981 by 2030. Thus the increasing prevalence of IBD is expected to drive market growth over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global crohn's disease treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global crohn's disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, Mylan N.V., Amgen Inc., and AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global crohn's disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global crohn's disease treatment market

Detailed Segmentation:

• Global Crohn's Disease Treatment Market, By Drug Type:
  • Antibiotics
  • Amino Salicylates
  • Corticosteroids
  • Immunomodulators
  • Others
• Global Crohn's Disease Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
• Global Crohn's Disease Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Janssen Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Mylan N.V.
  • Amgen Inc.
  • AstraZeneca

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Highlights
• Market Trends
• PORTER's Five Forces Analysis
• Epidemiology
• New Product Launch
• Product Type Innovation

4. Global Crohn's Disease Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global Crohn's Disease Treatment Market, By Drug Type, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Amino Salicylates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Immunomodulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Crohn's Disease Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• e-Commerce
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Crohn's Disease Treatment Market, By Region, 2017 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Janssen Biotech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us